SULFOSUCCINIMIDYL OLEATE
SULFOSUCCINIMIDYL OLEATE
SULFOSUCCINIMIDYL OLEATE 性质
| 熔点 | 220-2220C |
|---|---|
| 密度 | 1.19±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C Freezer |
| 溶解度 | 可溶于DMSO（轻微）、甲醇（轻微、加热） |
| 形态 | 固体 |
| 酸度系数(pKa) | -0.04±0.20(Predicted) |
| 颜色 | 白色至类白色 |
| 稳定性 | 吸湿性 |
| InChI | 1S/C22H37NO7S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(25)30-23-20(24)18-19(22(23)26)31(27,28)29;/h9-10,19H,2-8,11-18H2,1H3,(H,27,28,29); |
| InChIKey | IENDXPSKPJDQKO-UHFFFAOYSA-N |
| SMILES | CCCCCCCC/C=C\CCCCCCCC(ON1C(C(CC1=O)S([O-])(=O)=O)=O)=O.[Na+] |
SULFOSUCCINIMIDYL OLEATE 用途与合成方法
Sulfosuccinimidyl oleate (20 μM and 50 μM, 24 hours) alone does not alter the cellular viability. Exposure to 100 ng/ml LPS+5 ng/mL IFNγ modestly, yet significantly reduces the viability of the BV2 cells. Co-treatment with Sulfosuccinimidyl oleate prevents the LPS+IFNγ-induced reduction in the cell viability.
Sulfosuccinimidyl oleate (50 μM, 24 hours) co-treatment significantly reduces the LPS+IFNγ-induced expression of NOS2 and COX-2 in BV2 cells. Western blot analysis reveals a significant LPS/IFNγ-induced upregulation in the phosphorylated form of the p38, which is prevented by co-treatment with Sulfosuccinimidyl oleate (50 μM, 24 hours).
Cell Viability Assay
| Cell Line: | BV2 cells |
| Concentration: | 20 μM and 50 μM |
| Incubation Time: | 24 hours |
| Result: | Did not alter the viability of BV2 cells alone. Exposure of BV2 cells to 100 ng/mL LPS and 5 ng/mL IFNγ significantly reduced the viability of BV2 cells while simultaneous treatment with Sulfosuccinimidyl oleate prevented it. |
Western Blot Analysis
| Cell Line: | BV2 cells |
| Concentration: | 50 μM |
| Incubation Time: | 24 hours |
| Result: | Drastically increased the levels of NOS2, COX-2, and P-p38/T-p38. |
Sulfosuccinimidyl oleate (50 mg/kg; administered once by single oral gavage) significantly reduces the cortical ischemic infarct size compared to vehicle-treated controls in male BALB/cABom mice with pMCAo model. In addition, Sulfosuccinimidyl oleate at 50 mg/kg is suitable to see a beneficial effect after stroke.
| Animal Model: | 4-month-old male BALB/cABom mice with pMCAo model |
| Dosage: | 50 mg/kg |
| Administration: | Administered once by single oral gavage |
| Result: | Reduced brain damage following ischemia. Attenuated infarct size. |
SULFOSUCCINIMIDYL OLEATE 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-112847A | SULFOSUCCINIMIDYL OLEATE | 135661-44-8 | 5mg | 800 |
| 2026-09-15 | HY-112847A | SULFOSUCCINIMIDYL OLEATE | 135661-44-8 | 10mM * 1mLin DMSO | 848 |
